Previous evidence-based studies have compared the diagnostic performance of choline, fluciclovine, and PSMA PET/CT in PCa patients with BCR, and particularly at a PSA level less than 2 ng/mL6. This evidence concerns the gene FOLH1 and posterior cortical atrophy.